Skip to main content
Figure 3 | BMC Pulmonary Medicine

Figure 3

From: Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2

Figure 3

GC7 enhanced cisplatin sensitivity in NSCLC cells via inhibition of eIF5A-2. (A) eIF5A-2 siRNA inhibits eIF5A-2 in both A549 and NCI-H1299 cells. (B–C) Comparing changes in cisplatin sensitivity in A549 and NCI-H1299 NSCLC cells after treatment with eIF5A-2 siRNA alone or combined with GC7.

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us